Akero Therapeutics Faces Critical Deadline Amid Acquisition Scrutiny

Investors in Akero Therapeutics are bracing for a pivotal moment as the biopharmaceutical company approaches a decisive regulatory deadline. With the proposed acquisition by Novo Nordisk entering its final phase, the situation has grown increasingly complex due to legal investigations and disappointing financial performance.

The timeline for Novo Nordisk’s $5.2 billion acquisition offer reaches a crucial milestone on December 5, 2025, when the mandatory waiting period under the Hart-Scott-Rodino Act expires. This deadline requires U.S. antitrust authorities to issue their verdict on the proposed transaction. The acquisition terms include $54 per share in cash plus an additional $6 per share contingent value right, dependent on regulatory approval of the drug candidate Efruxifermin by 2031.

Complicating Read more...